X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ORCHID PHARMA LTD NATCO PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 13.8 -0.1 - View Chart
P/BV x 3.9 0.1 3,050.0% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 NATCO PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
ORCHID PHARMA LTD
Sep-13
NATCO PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,080194 556.7%   
Low Rs67135 1,918.0%   
Sales per share (Unadj.) Rs592.1276.5 214.2%  
Earnings per share (Unadj.) Rs188.4-79.2 -237.9%  
Cash flow per share (Unadj.) Rs206.3-43.5 -474.9%  
Dividends per share (Unadj.) Rs8.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs833.653.9 1,545.5%  
Shares outstanding (eoy) m36.9070.45 52.4%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x1.50.4 357.1%   
Avg P/E ratio x4.6-1.4 -321.5%  
P/CF ratio (eoy) x4.2-2.6 -161.0%  
Price / Book Value ratio x1.12.1 49.5%  
Dividend payout %4.40-   
Avg Mkt Cap Rs m32,3118,067 400.6%   
No. of employees `0004.82.8 172.5%   
Total wages/salary Rs m3,2562,527 128.8%   
Avg. sales/employee Rs Th4,522.56,956.1 65.0%   
Avg. wages/employee Rs Th674.0902.5 74.7%   
Avg. net profit/employee Rs Th1,439.0-1,993.0 -72.2%   
INCOME DATA
Net Sales Rs m21,84819,477 112.2%  
Other income Rs m404407 99.2%   
Total revenues Rs m22,25219,884 111.9%   
Gross profit Rs m9,2841,103 842.0%  
Depreciation Rs m6622,519 26.3%   
Interest Rs m1545,227 2.9%   
Profit before tax Rs m8,872-6,236 -142.3%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,920-125 -1,533.5%   
Profit after tax Rs m6,952-5,580 -124.6%  
Gross profit margin %42.55.7 750.6%  
Effective tax rate %21.62.0 1,077.9%   
Net profit margin %31.8-28.7 -111.1%  
BALANCE SHEET DATA
Current assets Rs m21,30711,014 193.5%   
Current liabilities Rs m5,92032,060 18.5%   
Net working cap to sales %70.4-108.1 -65.2%  
Current ratio x3.60.3 1,047.6%  
Inventory Days Days7395 77.2%  
Debtors Days Days10734 317.4%  
Net fixed assets Rs m14,98629,440 50.9%   
Share capital Rs m369705 52.4%   
"Free" reserves Rs m30,3532,043 1,486.0%   
Net worth Rs m30,7603,800 809.5%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m37,15146,510 79.9%  
Interest coverage x58.6-0.2 -30,349.2%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.60.4 140.4%   
Return on assets %19.1-0.8 -2,516.6%  
Return on equity %22.6-146.9 -15.4%  
Return on capital %29.3-3.7 -785.7%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m10,3227,513 137.4%   
Fx outflow Rs m2,9785,649 52.7%   
Net fx Rs m7,3431,865 393.8%   
CASH FLOW
From Operations Rs m4,6361,682 275.7%  
From Investments Rs m-11,155-9,860 113.1%  
From Financial Activity Rs m6,5096,644 98.0%  
Net Cashflow Rs m-18-1,535 1.2%  

Share Holding

Indian Promoters % 52.0 32.3 161.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 4.6 170.4%  
FIIs % 16.6 3.3 503.9%  
ADR/GDR % 0.0 4.6 -  
Free float % 26.0 55.3 47.0%  
Shareholders   25,395 84,811 29.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 150 Points Up; Oil & Gas Stocks Lead(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares show losses. The Nikkei 225 is up 0.3% while the Hang Seng is down 0.1%.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 14, 2018 12:07 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS